Viscort-6 is a tablets formulation containing Deflazacort IP. Derived from prednisolone; 6 mg deflazacort is equivalent to 5 mg prednisolone. Greater anti-inflammatory potency than prednisolone.
Step 01
A single-active formulation built on Deflazacort IP, transcribed from the composition panel exactly as printed.
Step 02
Presented as tablets in 10 × 10 Tablets. The pack panel carries the full handling direction.
Step 03
The pack prints 5 indications. They are reproduced on this page without addition; the prescribing decision stays with the physician.
Step 04
As directed by the Physician.
| Ingredient | Strength / Details |
|---|---|
| Deflazacort IP | 6 mg |
No filler copy and no borrowed claims. Each card names an active exactly as the Viscort-6 composition panel prints it, with its pharmacopoeial class and the strength on the carton.
Corticosteroid
6 mg
Deflazacort Tablets 6 mg.
Deflazacort Tablets 6 mg.
Derived from prednisolone; 6 mg deflazacort is equivalent to 5 mg prednisolone.
Greater anti-inflammatory potency than prednisolone.
From the printed panel
The Viscort-6 carton prints no onset, no duration of effect and no outcome, so none is published here. What it does document is a course — four phases, each carrying the panel text that governs it.
Tablets
Vistra Biotech Pharma
Patna, Bihar, India
Contact Vistra Biotech Pharma for distribution, PCD franchise, product dossiers, and business partnership opportunities for Viscort-6 and the complete Viscort product range.
Vistra Biotech Pharma — pharmaceutical marketing and distribution since June 2019.